New methods to improve brain stimulation for Parkinson's disease treatment.
Official title: Circuit-specific, chemogenetic neuromodulation in nonhuman primates.
Funded at Nathan S. Kline Institute for Psych Res · NIH-10854940 · Data updated 2026-11-12
This study is exploring new ways to improve brain treatments for Parkinson's disease by using special techniques to target specific brain areas, with the hope of making therapies safer and more effective for people living with the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nathan S. Kline Institute for Psych Res NIH-funded |
| Lab location | 1 site (Orangeburg, United States) |
| Project start | June 15, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,108,413 |
| NIH project number | 5UG3MH129381-02 |
| Project ID | NIH-10854940 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Parkinson's disease who may benefit from advanced neuromodulation therapies.
✕Less likely to help
Patients with conditions other than Parkinson's disease or those who are not suitable candidates for neuromodulation therapies may not receive benefits from this research.
What this research studies
This research aims to develop innovative neuromodulation techniques using chemogenetics in nonhuman primates to enhance the effectiveness of brain stimulation therapies for Parkinson's disease. By utilizing Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), the study focuses on selectively targeting specific brain circuits involved in motor symptoms. The approach includes advanced methods for delivering these receptors into neurons and assessing their impact through imaging and behavioral evaluations. Ultimately, the goal is to translate these findings into safer and more effective treatments for patients with Parkinson's disease.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Parkinson's disease, reducing the risks associated with current surgical options.
How similar studies have gone: Previous research has shown promise in using chemogenetic approaches for neuromodulation, indicating potential for success in this novel application.
Where this research is happening
-
Nathan S. Kline Institute for Psych Res
Orangeburg, United States Active
Researchers
- Principal investigator: Schroeder, Charles E — Nathan S. Kline Institute for Psych Res
- Study coordinator: Schroeder, Charles E
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Addressing racial disparities in opioid overdose deaths using open source peer recovery coaching and AI-powered mobile health
A small, open-source program uses AI-powered texting and peer recovery coaching to help Black and Latinx people who use opioids access support and stay in treatment, aiming to reduce overdose deaths and close gaps in care.
-
Hyperexcitability in Alzheimer's Disease and how it affects brain signals
Aimed at people with Alzheimer’s disease or related dementia, this grant studies abnormal brain activity that happens early in the disease and tests whether stopping it can help cognition and amyloid buildup.
-
Understanding how a brain visual pathway linked to social cues goes wrong in schizophrenia
Aiming to map and understand how a special brain visual pathway that helps read social cues may be disrupted in people with schizophrenia, to identify potential targets for future treatments.
-
Circuits for detecting surprising events in V1 (visual cortex)
This grant studies how the brain automatically notices unexpected visual events, focusing on autism-related brain processing, to understand how people with autism may experience and react to their surroundings.
-
CB1 signaling and alcohol effects in development
This project studies how alcohol exposure before birth changes brain signaling and behavior later in life, with a focus on CB1 receptors in the hippocampus and prefrontal cortex.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.